About
Coronis Partners is a leading Israeli Investment Company specializing in the biotechnology sector and focusing exclusively on highly select opportunities in the life sciences including therapeutics, diagnostic and agro-bio space. Coronis companies have demonstrated through superior management and financial planning - high growth, good financial stability and the ability to meet their development plans and goals. Since 2004, Coronis has invested over $10M in seven high quality portfolio companies. In 2007, four of Coronis companies issued public offerings BiondVax (TASE: BNDX) and Evogene (TASE: EVGN) in Tel Aviv; Rosetta Genomics (Nasdaq:ROSG) and Modigene (Nasdaq:MODG) at Nasdaq. Coronis performed partial exits in three of the four traded companies, with return on the initial price per share ranging between 5 to 6 fold in each of them (Evogene - Invested at $1 and Exited at $5; BiondVax - Invested at $0.45 and Exited at $2.26; Prolor - Invested at $1.5 and Exited at $8.6). The fifth company Glycominds has successfully completed a public offering in TASE in February 2011 (TASE: GLCM). Coronis Partners was active till the end of 2016.
Identity
| Name | Coronis Partners |
|---|---|
| Slug | coronis-partners |
| Type / kind | vc |
| Crunchbase ID | coronis-partners |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoLGFr4cLDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Dec 2016 |
| Last update | 2026-05-17 |
Location
| HQ country | Israel |
|---|---|
| HQ country code | IL |
| HQ city | Ness Ziona |
| HQ address | Golda Me'ir Street 5, Ness Ziona, Israel |
Web & social
| Website | http://www.coronis-partners.com/ |
|---|
Classifications
Funding
| Total raised | — |
|---|
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}